192 related articles for article (PubMed ID: 11535341)
1. CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV).
Hancock GE; Heers KM; Smith JD; Scheuer CA; Ibraghimov AR; Pryharski KS
Vaccine; 2001 Sep; 19(32):4874-82. PubMed ID: 11535341
[TBL] [Abstract][Full Text] [Related]
2. The immunogenicity of subunit vaccines for respiratory syncytial virus after co-formulation with aluminum hydroxide adjuvant and recombinant interleukin-12.
Hancock GE; Smith JD; Heers KM
Viral Immunol; 2000; 13(1):57-72. PubMed ID: 10733169
[TBL] [Abstract][Full Text] [Related]
3. Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles.
Garlapati S; Garg R; Brownlie R; Latimer L; Simko E; Hancock RE; Babiuk LA; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
Vaccine; 2012 Jul; 30(35):5206-14. PubMed ID: 22713718
[TBL] [Abstract][Full Text] [Related]
4. A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models.
Lambert SL; Aslam S; Stillman E; MacPhail M; Nelson C; Ro B; Sweetwood R; Lei YM; Woo JC; Tang RS
PLoS One; 2015; 10(3):e0119509. PubMed ID: 25793508
[TBL] [Abstract][Full Text] [Related]
5. A unique combination adjuvant modulates immune responses preventing vaccine-enhanced pulmonary histopathology after a single dose vaccination with fusion protein and challenge with respiratory syncytial virus.
Lee Y; Ko EJ; Kim KH; Lee YT; Hwang HS; Kwon YM; Graham BS; Kang SM
Virology; 2019 Aug; 534():1-13. PubMed ID: 31163351
[TBL] [Abstract][Full Text] [Related]
6. IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge.
Johnson TR; Parker RA; Johnson JE; Graham BS
J Immunol; 2003 Feb; 170(4):2037-45. PubMed ID: 12574374
[TBL] [Abstract][Full Text] [Related]
7. QS-21 synergizes with recombinant interleukin-12 to create a potent adjuvant formulation for the fusion protein of respiratory syncytial virus.
Hancock GE; Heers KM; Smith JD
Viral Immunol; 2000; 13(4):503-9. PubMed ID: 11192297
[TBL] [Abstract][Full Text] [Related]
8. Delta inulin-derived adjuvants that elicit Th1 phenotype following vaccination reduces respiratory syncytial virus lung titers without a reduction in lung immunopathology.
Wong TM; Petrovsky N; Bissel SJ; Wiley CA; Ross TM
Hum Vaccin Immunother; 2016 Aug; 12(8):2096-2105. PubMed ID: 27215855
[TBL] [Abstract][Full Text] [Related]
9. Prefusion RSV F Immunization Elicits Th2-Mediated Lung Pathology in Mice When Formulated With a Th2 (but Not a Th1/Th2-Balanced) Adjuvant Despite Complete Viral Protection.
Eichinger KM; Kosanovich JL; Gidwani SV; Zomback A; Lipp MA; Perkins TN; Oury TD; Petrovsky N; Marshall CP; Yondola MA; Empey KM
Front Immunol; 2020; 11():1673. PubMed ID: 32849580
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with the RSV fusion protein formulated with a combination adjuvant induces long-lasting protective immunity.
Garg R; Latimer L; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
J Gen Virol; 2014 May; 95(Pt 5):1043-1054. PubMed ID: 24572813
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein.
Johnson TR; Rothenberg ME; Graham BS
J Leukoc Biol; 2008 Sep; 84(3):748-59. PubMed ID: 18519743
[TBL] [Abstract][Full Text] [Related]
12. Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology.
Cyr SL; Jones T; Stoica-Popescu I; Brewer A; Chabot S; Lussier M; Burt D; Ward BJ
Vaccine; 2007 Jul; 25(29):5378-89. PubMed ID: 17561317
[TBL] [Abstract][Full Text] [Related]
13. Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus.
Hancock GE; Speelman DJ; Heers K; Bortell E; Smith J; Cosco C
J Virol; 1996 Nov; 70(11):7783-91. PubMed ID: 8892899
[TBL] [Abstract][Full Text] [Related]
14. Formulation with CpG oligodeoxynucleotides prevents induction of pulmonary immunopathology following priming with formalin-inactivated or commercial killed bovine respiratory syncytial virus vaccine.
Oumouna M; Mapletoft JW; Karvonen BC; Babiuk LA; van Drunen Littel-van den Hurk S
J Virol; 2005 Feb; 79(4):2024-32. PubMed ID: 15681404
[TBL] [Abstract][Full Text] [Related]
15. Immunoprotective activity and safety of a respiratory syncytial virus vaccine: mucosal delivery of fusion glycoprotein with a CpG oligodeoxynucleotide adjuvant.
Prince GA; Mond JJ; Porter DD; Yim KC; Lan SJ; Klinman DM
J Virol; 2003 Dec; 77(24):13156-60. PubMed ID: 14645572
[TBL] [Abstract][Full Text] [Related]
16. Formulation with CpG oligodeoxynucleotides increases cellular immunity and protection induced by vaccination of calves with formalin-inactivated bovine respiratory syncytial virus.
Mapletoft JW; Oumouna M; Townsend HG; Gomis S; Babiuk LA; van Drunen Littel-van den Hurk S
Virology; 2006 Sep; 353(2):316-23. PubMed ID: 16828832
[TBL] [Abstract][Full Text] [Related]
17. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.
Widjojoatmodjo MN; Bogaert L; Meek B; Zahn R; Vellinga J; Custers J; Serroyen J; Radošević K; Schuitemaker H
Vaccine; 2015 Oct; 33(41):5406-5414. PubMed ID: 26319741
[TBL] [Abstract][Full Text] [Related]
18. Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection.
Hancock GE; Speelman DJ; Frenchick PJ; Mineo-Kuhn MM; Baggs RB; Hahn DJ
Vaccine; 1995 Mar; 13(4):391-400. PubMed ID: 7793137
[TBL] [Abstract][Full Text] [Related]
19. Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection.
Srikiatkhachorn A; Braciale TJ
J Exp Med; 1997 Aug; 186(3):421-32. PubMed ID: 9236194
[TBL] [Abstract][Full Text] [Related]
20. IL-13 is required for eosinophil entry into the lung during respiratory syncytial virus vaccine-enhanced disease.
Castilow EM; Meyerholz DK; Varga SM
J Immunol; 2008 Feb; 180(4):2376-84. PubMed ID: 18250447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
